USFDA concludes PAI at Emcure Pharmaceuticals’ Gujarat manufacturing facility

10 Jul 2025 Evaluate

United States Food and Drug Administration (USFDA) has concluded Pre-Approval Inspection (PAI) at Emcure Pharmaceuticals’ manufacturing facility (Oncology) located at Sanand, Ahmedabad, Gujarat. The said inspection was conducted from June 30, 2025 to July 08, 2025. The inspection concluded without issuance of Form 483 (zero observations). 

Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.

Emcure Pharma Share Price

1395.15 -9.10 (-0.65%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×